Yayın:
Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: A multicenter retrospective analysis

dc.contributor.authorArtan, Ayse Serra
dc.contributor.authorMirioglu, Safak
dc.contributor.authorHocaoglu, Rabia Hacer
dc.contributor.authorTurgutalp, Kenan
dc.contributor.authorBoz, Saide Elif Gullulu
dc.contributor.authorEren, Necmi
dc.contributor.authorDincer, Mevlut Tamer
dc.contributor.authorUzun, Sami
dc.contributor.authorSahin, Gulizar
dc.contributor.authorKutlay, Sim
dc.contributor.authorCevher, Simal Koksal
dc.contributor.authorDheir, Hamad
dc.contributor.authorYilmaz, Murvet
dc.contributor.authorBasturk, Taner
dc.contributor.authorTatar, Erhan
dc.contributor.authorKurultak, Ilhan
dc.contributor.authorÖzturk, Ramazan
dc.contributor.authorArikan, Hakki
dc.contributor.authorYadigar, Serap
dc.contributor.authorTunca, Onur
dc.contributor.authorTurkmen, Kultigin
dc.contributor.authorElcioglu, Omer Celal
dc.contributor.authorKaya, Bulent
dc.contributor.authorKarakan, Sebnem
dc.contributor.authorAyar, Yavuz
dc.contributor.authorGul, Cuma Bulent
dc.contributor.authorYazici, Halil
dc.contributor.authorÖzturk, Savas
dc.contributor.buuauthorGÜLLÜLÜ BOZ, SAİDE ELİF
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.departmentNefroloji Ana Bilim Dalı
dc.contributor.researcheridJCX-3921-2023
dc.date.accessioned2025-02-19T05:14:44Z
dc.date.available2025-02-19T05:14:44Z
dc.date.issued2024-10-01
dc.description.abstractBackground We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort. Methods In this registry study, 558 patients from 47 centers who were treated with at least one immunosuppressive agent and had adequate follow-up data were included. Primary outcome was defined as complete (CR) or partial remission (PR). Secondary composite outcome was at least a 50% reduction in estimated glomerular filtration (eGFR), initiation of kidney replacement therapies, development of stage 5 chronic kidney disease, or death. Results Median age at diagnosis was 48 (IQR: 37-57) years, and 358 (64.2%) were male. Patients were followed for a median of 24 (IQR: 12-60) months. Calcineurin inhibitors (CNIs) with or without glucocorticoids were the most commonly used regimen (43.4%), followed by glucocorticoids and cyclophosphamide (GC-CYC) (39.6%), glucocorticoid monotherapy (25.8%), and rituximab (RTX) (9.1%). Overall remission rate was 66.1% (CR 26.7%, PR 39.4%), and 59 (10.6%) patients reached secondary composite outcome. Multivariate logistic regression showed that baseline eGFR (OR 1.011, 95% CI: 1.003-1.019, p = 0.007), serum albumin (OR 1.682, 95% CI: 1.269-2.231, p < 0.001), and use of RTX (OR 0.296, 95% CI: 0.157-0.557, p < 0.001) were associated with remission rates; whereas only lower baseline hemoglobin was significantly associated with secondary composite outcome (OR: 0.843, 95% CI: 0.715-0.993, p = 0.041). CYC use was significantly associated with higher remission (OR 1.534, 95% CI: 1.027-2.290, p = 0.036). Conclusions Higher baseline eGFR and serum albumin levels correlated with increased remission rates. Remission rates were lower in patients treated with RTX, while those on GC-CYC showed higher rates of remission. Due to the study's retrospective nature and multiple treatments used, caution is warranted in interpreting these findings.
dc.identifier.doi10.1186/s12882-024-03784-8
dc.identifier.eissn1471-2369
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85205527502
dc.identifier.urihttps://doi.org/10.1186/s12882-024-03784-8
dc.identifier.urihttps://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03784-8
dc.identifier.urihttps://hdl.handle.net/11452/50512
dc.identifier.volume25
dc.identifier.wos001326720700004
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherBMC
dc.relation.journalBmc Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectFollow-up
dc.subjectMethylprednisolone
dc.subjectCyclophosphamide
dc.subjectChlorambucil
dc.subjectRituximab
dc.subjectTrial
dc.subjectCyclosporine
dc.subjectTacrolimus
dc.subjectSteroids
dc.subjectReceptor
dc.subjectMembranous nephropathy
dc.subjectImmunosuppression
dc.subjectChronic kidney disease
dc.subjectRemission
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectUrology & nephrology
dc.titleObservational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: A multicenter retrospective analysis
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı/Nefroloji Ana Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublication63440f8c-694e-4dff-b787-86d3c7cc2bc6
relation.isAuthorOfPublication.latestForDiscovery63440f8c-694e-4dff-b787-86d3c7cc2bc6

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Küçük Resim
Ad:
Boz_vd_2024.pdf
Boyut:
786.61 KB
Format:
Adobe Portable Document Format